Amgen and Kite Pharma announced a strategic research collaboration and license agreement to develop and commercialize CAR T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's array of cancer targets. Kite received $60M upfront and was eligible for up to $525M in milestones per Amgen program plus tiered royalties; Amgen also eligible for $525M per Kite program.
Key facts
AnnouncedJan 05, 2015
ClosedJan 05, 2015
Deal value$585M
Deal typeCo-Development
Therapeutic areaHematologic and solid tumors
IndicationsHematologic and solid tumors
Key assetsCAR-T cell therapy candidates against Amgen oncology targets
MechanismEngineered autologous CD19/multi-target chimeric antigen receptor (CAR) T cell immunotherapy